A proposal for rituximab treatment in patients with myasthenia gravis

  • Konno Shingo
    Department of Neurology, Toho University Ohashi Medical Center

Bibliographic Information

Other Title
  • リツキシマブ治療施行経験と提言

Search this article

Description

Rituximab (RTX) is a chimeric murine/human monoclonal antibody directed against the CD20 surface antigen of B cells. RTX has been for the treatment of non-Hodikin lymphoma. Recently, RTX was shown to be effective in treating patients with myasthenia gravis (MG) who did not show improvement with other immunomodulation treatments. However, the evidence of its efficacy is mostly limited to a few case series or open-label trials. At the present stage, RTX may be permitted to be used in patients who understand the risk of its side effects and provide consent for its use in treatment. In future, it will be necessary to establish an effective and safe medication protocol of RTX in Japan.

Journal

  • Rinsho Shinkeigaku

    Rinsho Shinkeigaku 53 (11), 1312-1314, 2013

    Societas Neurologica Japonica

References(9)*help

See more

Details 詳細情報について

  • CRID
    1390282680012609408
  • NII Article ID
    130004505428
  • DOI
    10.5692/clinicalneurol.53.1312
  • COI
    1:STN:280:DC%2BC2c3itlynug%3D%3D
  • ISSN
    18820654
    0009918X
  • PubMed
    24291971
  • Text Lang
    ja
  • Article Type
    journal article
  • Data Source
    • JaLC
    • Crossref
    • PubMed
    • CiNii Articles
    • OpenAIRE
  • Abstract License Flag
    Disallowed

Report a problem

Back to top